Neumora Therapeutics (NMRA) Earnings Date, Estimates & Call Transcripts → 🚀 Tap into this explosive trade opportunity asap (From Daily Strike Alliance) (Ad) Free NMRA Stock Alerts $9.90 +0.21 (+2.17%) (As of 05/31/2024 ET) Add Compare Share Share EarningsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Earnings SummaryUpcoming Earnings DateAug. 6EstimatedActual EPS (May. 7) -$0.34 Consensus EPS (May. 7) -$0.34 Skip Charts & View Estimated and Actual Earnings DataEarnings Per ShareRevenueNMRA Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.NMRA Estimated and Actual Revenue by Quarter Estimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad Wall Street StarThis Apple-like Innovator is Revolutionizing HealthcareAI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.Click here to learn more about the booming eHealth industry Neumora Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20241($1.56)($1.56)($1.56)Q2 20241($1.59)($1.59)($1.59)Q3 20241($0.37)($0.37)($0.37)Q4 20241($1.28)($1.28)($1.28)FY 20244($4.80)($4.80)($4.80)Q1 20251($0.38)($0.38)($0.38)Q2 20251($0.39)($0.39)($0.39)Q3 20251($0.39)($0.39)($0.39)Q4 20251($0.40)($0.40)($0.40)FY 20254($1.56)($1.56)($1.56)NMRA Earnings Date and InformationNeumora Therapeutics last issued its earnings data on May 7th, 2024. The reported ($0.34) earnings per share for the quarter, meeting the consensus estimate of ($0.34). Neumora Therapeutics has generated $0.00 earnings per share over the last year. Earnings for Neumora Therapeutics are expected to decrease in the coming year, from ($1.46) to ($1.54) per share. Neumora Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, August 6th, 2024 based off prior year's report dates.Read More Neumora Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript 8/6/2024(Estimated)------- 5/7/2024Q1 2024($0.34)($0.34)-($0.34)--3/7/2024Q4 2023($0.76)($0.71)+$0.05($0.71)--11/1/2023Q3 2023($0.35)($1.14)($0.79)($1.14)-- Neumora Therapeutics Earnings - Frequently Asked Questions When is Neumora Therapeutics's earnings date? Neumora Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, August 6th, 2024 based off last year's report dates. Learn more on NMRA's earnings history. Did Neumora Therapeutics beat their earnings estimates last quarter? In the previous quarter, Neumora Therapeutics (NASDAQ:NMRA) reported ($0.34) earnings per share (EPS) to hit the analysts' consensus estimate of ($0.34). Learn more on analysts' earnings estimate vs. NMRA's actual earnings. How much profit does Neumora Therapeutics generate each year? Neumora Therapeutics (NASDAQ:NMRA) has a recorded net income of -$235.93 million. NMRA has generated $0.00 earnings per share over the last four quarters. What is Neumora Therapeutics's EPS forecast for next year? Neumora Therapeutics's earnings are expected to decrease from ($1.46) per share to ($1.54) per share in the next year. More Earnings Resources from MarketBeat Related Companies: Halozyme Therapeutics Earnings CRISPR Therapeutics Earnings Krystal Biotech Earnings ImmunityBio Earnings Immunovant Earnings SpringWorks Therapeutics Earnings Apogee Therapeutics Earnings Iovance Biotherapeutics Earnings Arcellx Earnings Denali Therapeutics Earnings Earnings Tools: Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country: U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Australia Earnings Reports Latest Articles: Hormel: A Potential Buy Despite Post-Earnings DeclineCanopy Growth’s Earnings: Profitability Despite Industry ShiftsAbercrombie & Fitch First Quarter Earnings Surge to New HeightsTD Bank Q2 Earnings: Record Highs and Regulatory HurdlesPDD Holdings Earnings Volatility Alerts Buyers Zoom Stock’s Earnings Volatility Picked Up a Lot of BuyersBaidu Stock Earnings Prove Ray Dalio Right about China? This page (NASDAQ:NMRA) was last updated on 5/31/2024 by MarketBeat.com Staff From Our PartnersExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersBill Clinton Backing Biden Replacement???The Freeport SocietyShocking $16T Elon Musk Crypto LeakCrypto 101 MediaGet out of dollars—get into America’s new money insteadStansberry ResearchThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarWrite this ticker symbol down…StocksToTradeGold Set to EXPLODE!Gold Safe ExchangeDo This Before July 30 2024 To Claim Trump’s Gift Wealthpin Pro Adding Choose a watchlist: Watchlist My Default Watchlist Adding Neumora Therapeutics, Inc. You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.